Press Releases Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-05 EST			5-day change	1st Jan Change
5.240 ^USD	-1.32%		-0.38%	-27.32%

12-01	Altimmune, Inc. Announces CEO Changes	CI
12-01	Altimmune, Inc. Announces Executive Changes	CI

Press Releases

Altimmune Announces CEO Transition and Succession Plan	12-01	AQ
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference	11-26	AQ
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting 2025	11-12	AQ
Presentation: A Phase 2, Multicenter, Randomized, Placebo-Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis	11-11	PU
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025	11-11	AQ
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025	11-07	AQ
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates	11-06	AQ
Altimmune to Participate in Two Upcoming Investor Conferences	11-05	AQ
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder	11-03	AQ
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025	10-30	AQ
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025	10-20	AQ
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm	10-07	PR
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune	10-06	BU
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders	10-06	PR
Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT	10-03	PR
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune	10-03	PR
ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit	10-02	PR
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm	10-02	PR
Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT	10-01	PR
Altimmune, Inc. (NASDAQ: ALT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit	10-01	PR
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm	09-30	PR
Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT	09-30	BU
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit	09-29	PR
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT	09-29	PR
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide	09-29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Press Releases

Filters